Four Decades of Research in Alzheimer’s Disease (1975–2014): A Bibliometric and Scientometric Analysis

Abstract

Background Bibliometric and scientometric methods can be applied to the study of a research field. Objective We hypothesized that a bibliometric and scientometric analysis of the Alzheimer’s disease (AD) research field could render trends that provide researchers and funding agencies valuable insight into the history of the field, current tendencies, and potential future directions. Methods We performed searches in publicly available databases including PubMed, Scopus, Web of Science, and Alzheimer’s Funding Analyzer for the period 1975–2014, and conducted a curve fitting analysis with non-linear regression. Results While the rate and impact of publications continue to increase, the number of patents per year is currently declining after peaking in the late 2000s, and the funding budget has plateaued in the last 5–10 years analyzed. Genetics is the area growing at a fastest pace, whereas pathophysiology and therapy have not grown further in the last decade. Among the targets of pathophysiology research, amyloid-β continues to be the focus of greatest interest, with tau and apolipoprotein E stagnant after a surge in the 1990s. The role of inflammation, microglia, and the synapse are other research topics with growing interest. Regarding preventative strategies, education attainment, diet, and exercise are recently gaining some momentum, whereas NSAIDs and statins have lost the spotlight they once had. Conclusion Our bibliometric and scientometric analysis provides distinct trends in AD research in the last four decades, including publication and patent output, funding, impact, and topics. Our findings could inform the decision-making of research funding agencies in the near future.

Global Mapping of Interventions to Improve Quality of Life of Patients with Alzheimer’s Disease during 1990–2018

“…However, it seems that there is a robust interest within the 5 years from 2010 to 2014 (i.e., total usage and mean usage rate), which tended to decrease afterwards. This pattern may indicate the reduction of investments of private organizations, venture capital, and federal agencies in developing new drugs for AD [27,28]. The previous literature has reported the failures and negative findings in developing new therapies for AD as a potential reason for the tight funding for advanced research in AD.…”

Is Alzheimer’s Disease Risk Modifiable?

“…AD affects 5.4 million Americans and is the fifth leading cause of death among Americans aged 65 years or older [3]. While we have witnessed considerable advances in our understanding of its molecular and cellular underpinnings in the last four decades [4], AD remains incurable.…”

The role of interregional relationships in research talent development

“…Within this approach, the main focus is made on the national economy's ability to benefit from the intellectual capabilities of the research staff [19, p. 20]. The problem of the role that research talent plays in building an innovative economy is discussed in a number of other studies [20][21][22][23][24][25][26][27][28][29][30][31][32]).…”